Zurcher Kantonalbank Zurich Cantonalbank Purchases New Position in Enhabit, Inc. (NYSE:EHAB)

Posted by on Feb 15th, 2023

Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Enhabit, Inc. (NYSE:EHAB – Get Rating) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 142,316 shares of the company’s stock, valued at approximately $1,998,000. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.29% of Enhabit as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. IFP Advisors Inc bought a new stake in shares of Enhabit during the 3rd quarter worth approximately $39,000. CI Investments Inc. bought a new stake in shares of Enhabit during the 2nd quarter worth approximately $27,000. South Dakota Investment Council bought a new stake in shares of Enhabit during the 3rd quarter worth approximately $45,000. KBC Group NV bought a new stake in shares of Enhabit during the 3rd quarter worth approximately $54,000. Finally, Signaturefd LLC bought a new stake in shares of Enhabit during the 3rd quarter worth approximately $64,000. Institutional investors and hedge funds own 95.55% of the company’s stock.

Enhabit Stock Down 0.6 %

Shares of NYSE EHAB opened at $14.23 on Wednesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.50 and a current ratio of 1.50. Enhabit, Inc. has a 52-week low of $11.65 and a 52-week high of $25.25. The firm has a 50 day moving average price of $13.98 and a two-hundred day moving average price of $14.07.

Wall Street Analysts Forecast Growth

EHAB has been the subject of several research reports. UBS Group initiated coverage on shares of Enhabit in a research note on Thursday, December 8th. They issued a “sell” rating and a $12.00 price objective for the company. CJS Securities initiated coverage on shares of Enhabit in a research note on Tuesday, December 13th. They issued a “market perform” rating and a $18.00 price objective for the company. Credit Suisse Group dropped their price objective on shares of Enhabit from $19.00 to $15.00 and set a “neutral” rating for the company in a research note on Friday, November 4th. Finally, Stifel Nicolaus initiated coverage on shares of Enhabit in a research note on Monday, December 5th. They issued a “buy” rating and a $17.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $16.43.

Enhabit Company Profile

(Get Rating)

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.

Read More

Institutional Ownership by Quarter for Enhabit (NYSE:EHAB)

Receive News & Ratings for Enhabit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enhabit and related companies with MarketBeat.com's FREE daily email newsletter.